Immunotherapy with chemoradiation for advanced cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new drug called Enlonstobart, which helps the immune system fight cancer, given with standard chemotherapy and radiation for patients with locally advanced cervical cancer. The goal is to see if this combination is effective and safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have cervical cancer that has not spread to distant organs (stage III or IVA).
- You have not had any prior treatment for this cancer.
- You are generally healthy and able to care for yourself (ECOG 0-1).
- Your heart, liver, kidneys, and blood counts are within acceptable ranges.
- You have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemoradiation for locally advanced cervical cancer caused by HPV. It may be an option for women with stage 3-4A disease or positive lymph nodes who have not had immunotherapy before.
This trial tests a combination of short-course radiation, two chemotherapy drugs (liposomal irinotecan and capecitabine), and an immunotherapy drug (Enlonstobart) for people with locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor before surgery.
This trial tests a new drug called enlansibumab (an immunotherapy that helps your immune system fight cancer) given with standard chemotherapy and radiation for locally advanced cervical cancer. It aims to see if adding this drug improves outcomes for patients whose cancer has spread to nearby lymph nodes but not to distant organs.
This trial tests a new drug (QL1706) combined with chemotherapy before the usual radiation therapy for locally advanced cervical cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This study tests whether adding immunotherapy to chemotherapy, then giving chemotherapy together with radiation, works better for advanced cervical cancer. It aims to improve cancer control and help people live longer, without major safety issues.
This trial tests a new treatment that combines an immunotherapy drug (cadonilimab) with chemotherapy for people with locally advanced cervical cancer. The goal is to see if this combination can shrink the tumor enough to make surgery possible or more effective.
Hear when a new Uterine Cervical Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.